Prosigna
PAM50/ROR breast-cancer prognostic classifier; historical FDA-cleared nCounter IVD and current US NGS LDT are distinct configurations.
- Developer
- Veracyte
- Intended use
- Risk Stratification
- Cancer scope
- Breast cancer
- Specimen
- Breast tumor tissue
- Molecular modality
- RNA expression
- Current version
- Current US whole-transcriptome NGS Prosigna LDT
- Evidence context
- 2 structured studies · 0 indexed performance results · 2 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.